<html>
<!-- DW6 -->
<head>
<title>Cell Signaling Tutorial</title>
 
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
</head>

<body bgcolor="FDF5E6" vlink="#0000FF" background="../../../dnabckgd2.gif">
<!--Begin table to constrain text to 500 pixels wide-->
<table width=600 align="center">
  <tr> 
    <td valign="top"> <center>
      <img src="../../banners/cell_bio.GIF" width="387" height="20" border="0" usemap="#Map">    
    </center>
      <p><a href="../../../default.html"><font size="2">The Biology Project</font></a> 
        <font size="2"><b><font color="#006600">&gt;</font></b> <a href="../../cell_bio.html">Cell
        Biology</a> <b><font color="#006600">&gt;</font></b> 
        <a href="Index.html">Cell Signaling</a><b><font color="#006600"> &gt;</font></b> <font color="#006600">Problem
        Set</font> </font><!--HEADINGS-->
      </p>
      <h2 align=CENTER> <font color="#25 7A 24"> <font color="006600">Cell Signaling 
        Problem Set</font></font> </h2>
      <h3 align=CENTER> <font color="#25 7A 24"> <font color="#25 7A 24"><font color="006600">Problem 
        12: Cancer Therapy</font></font><font color="#25 7A 24"><font color="006600"></font></font></font></h3>      
      <p><strong><font color="#006600">Tutorial to help answer the question</font></strong></p>      <p>A new drug, STI-571 or Gleevec, specifically inhibits the Abl tyrosine 
        kinase that is mutated in chronic myeloid leukemia. Treating patients 
        with the drug dramatically improves survival, but people with a &quot;blast 
        crisis&quot; form of the cancer begin to develop resistance. Which of 
        the following statements are important conclusions from studies on the 
        use of STI-571 in cancer treatment?<font color="#FF0000"> </font></p>      <blockquote> 
        <table>
          <tr> 
            <td width="5%" valign="top"><b>A</b>. </td>
            <td width="95%">Inhibiting signaling pathways can benefit people with cancer.</td>
          </tr>
          <tr> 
            <td width="5%" valign="top"><b>B.</b></td>
            <td width="95%">Rapidly dividing cancer cells that have lost checkpoint 
              systems insuring genome fidelity can develop resistance to specific 
              anti-cancer drugs.</td>
          </tr>
          <tr> 
            <td width="5%" valign="top"><b>C</b>.</td>
            <td width="95%">Acquisition of resistance to STI-571 shows that the 
              same specific enzyme changes occur, suggesting that developing new 
              drugs that target mutations leading to resistance may further improve 
              patient survival.</td>
          </tr>
          <tr> 
            <td width="5%" valign="top"><b>D.</b></td>
            <td width="95%">All of the above.</td>
          </tr>
        </table>
        <h2 align="center"><font color="#006600">Tutorial</font></h2>
        <CENTER>
        </CENTER>
        <h3><font color="#006600">Cancer therapy</font></h3>
        <p>Cell signaling systems are particularly important in cancer. The disease 
          results from genetic changes in cells that frequently alter signaling 
          systems and pathways. </p>
        <font color="#006600"><b>Inhibiting the BCR-ABL tyrosine kinase in chronic 
        myeloid leukemia (CML)</b></font><br>
        Reference: <em>New England Journal of Medicine</em> 344, 1084 (2001). 
        <P>
<CENTER>
          </CENTER>
<ul>
	      <li>CML results from cells that undergo rapid proliferation. The cancer is 
            always accompanied by a genetic translocation between chromosomes 
            9 and 22, producing an activated tyrosine kinase called BCR-ABL.</li>
	      <LI>Brian Druker, a scientist at Oregon University, discovered an inhibitor 
            called STI-571 (Gleevec) that blocks the BCR-ABL tyrosine kinase. 
            The inhibitor design was possible because the complete structure of 
            the ATP binding site was known. 
          <LI>Treating patients with CML who had failed all other standard
	  therapies showed a high percentage with tumor regression including complete remissions.
	      <LI>In one study, 53 out of 54 cancer patients showed complete lasting responses. 
          <LI>The inhibitor also inhibits another kinase (C-kit) that is important in metastatic gastrointestinal stromal tumor, and a
	  recent study (<em>New England Journal of Medicine</em> 344, 1052 (2001)) showed metastataic tumor regression in a cancer that had
	  previously been considered to be untreatable and always fatal.
	 
</ul>
        <h3><font color="#006600">Patients who relapse</font></h3>
        <ul>
	      <li>Patients in the early or chronic stage of CML show complete lasting responses 
            (53/54 in one study).</li>
	<LI>In later stages, the disease enters a blast-crisis and frequently shows loss of p53, an important tumor 
	suppressor that helps prevent chromosomal errors. 
	Treating with STI-571 reduces tumor load, but 
	many of the patients relapse.</LI>
</ul>
<CENTER>
        </CENTER>
        <h3><font color="#006600">Why does STI-571 sometimes fail?</font></h3>
<ul>
	<li>Reference: <em>Science </em>293, 876 (2001)- Replacement of threonine by isoleucine in BCR-ABL
	  retains kinase activity but eliminates binding by STI-571.</li>
	<LI>Most relapsing patients had this single mutation.
	<LI>These results imply that designing a new drug that can block the mutant
	  BCR-ABL kinase.
	<LI>This represents targeted therapy, directed against the mutation(s) that
	  lead to a cancer cell phenotype.  This should both be safer and much more
	  effective than current therapies.
</ul>
</blockquote> 
        <center>
        <a href="12q.html">Problem 12</a> | 
        <a href="12a.html">Answer</a>  
      </center> <p align=left> <a href="../../../default.html"><font size="2">The Biology
            Project</font></a> <font size="2"><b><font color="#006600">&gt;</font></b> <a href="../../cell_bio.html">Cell
            Biology</a> <b><font color="#006600">&gt;</font></b> <a href="Index.html">Cell
            Signaling</a><b><font color="#006600"> &gt;</font></b> <font color="#006600">Problem
      Set</font></font></p>
            <hr> <center>
        <div align="center"><font size="2"><a href="../../../DEFAULT.html">The
              Biology Project</a> <br>
              <a href="http://www.biochem.arizona.edu/" target="_blank">Department of Biochemistry and Molecular Biophysics</a> <br>
              <a href="http://www.arizona.edu/" target="_blank">University of Arizona</a> <br>
  <font size=2>May<font size=2> 2002</font></font><br>
  Revised: August 2004 <br>
  <a href = "http://biology.arizona.edu/contact/default.html" target="_blank">Contact the Development
  Team</a> </font></div>
        <p align="center"><font size="2"> http://biology.arizona.edu <br>
  All contents copyright &copy; 2002-04. All rights reserved. </font>        
        <font size="2"><p></font> 
      </center>
      <!--End table to constrain text to 600 pixels wide-->
    </td>
  </tr>
</table>
<map name="Map">
  <area shape="rect" coords="1,1,226,26" href="../../../DEFAULT.html" alt="The Biology Project">
  <area shape="rect" coords="236,1,400,26" href="../../cell_bio.html" alt="Cell Biology">
</map>
</body>
</html>
